XML 28 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Stockholders' Equity Stockholders' Equity
Equity Incentive Plan
In June 2009, our board of directors adopted and approved our 2009 Stock Plan (the "2009 Plan"), which provides for the issuance of stock options, Restricted Stock Awards ("RSAs") and Restricted Stock Units ("RSUs") to qualified employees, directors and consultants. Stock options granted under our 2009 Plan have a maximum life of 10 years and an exercise price not less than 100% of the fair market value of our common stock on the date of grant. RSUs granted under our 2009 Plan have a maximum life of seven years. No shares of our common stock were reserved for future issuance under our 2009 Plan as of June 30, 2023.
Our 2019 Omnibus Incentive Plan ("2019 Plan") became effective upon closing of our initial public offering and succeeds our 2009 Plan. Our 2019 Plan provides for the issuance of stock options, RSAs, RSUs and other equity- or cash-based awards to qualified employees, directors and consultants. Stock options granted under our 2019 Plan have a maximum life of 10 years and an exercise price not less than 100% of the fair market value of our common stock on the date of grant. 142,138,182 shares of our Class A common stock were reserved for future issuance under our 2019 Plan as of June 30, 2023.
The number of shares of our Class A common stock available for issuance under the 2019 Plan will be increased by the number of shares of our Class B common stock subject to awards outstanding under our 2009 Plan that would, but for the terms of the 2019 Plan, have returned to the share reserves of the 2009 Plan pursuant to the terms of such awards, including as the result of forfeiture, repurchase, expiration or retention by us in order to satisfy an award’s exercise price or tax withholding obligations. In addition, the number of shares of our Class A common stock reserved for issuance under our 2019 Plan will automatically increase on the first day of each fiscal year through and including January 1, 2029, in an amount equal to 5% of the total number of shares of our Class A common stock and our Class B common stock outstanding on the last day of the calendar month before the date of each automatic increase, or a lesser number of shares determined by our board of directors.
Stock Option Activity
Stock option activity during the six months ended June 30, 2023, was as follows (in thousands, except per share amounts):
Stock Options Outstanding
SharesWeighted-Average Exercise PriceWeighted-Average Remaining Contractual Term
Aggregate Intrinsic
Value (1)
(in years)
Outstanding as of December 31, 202215,799$13.25 6.1$174,165 
Exercised (1,275)2.63 
Outstanding as of June 30, 202314,524$14.18 6.0$190,996 
Exercisable as of June 30, 20237,433$8.64 3.2$139,004 
(1)We calculate intrinsic value based on the difference between the exercise price of in-the-money-stock options and the fair value of our common stock as of the respective balance sheet date.
The total grant-date fair value of stock options vested during the six months ended June 30, 2023 and 2022, was $14.2 million and $1.6 million, respectively. The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2023 and 2022 was $29.4 million and $83.3 million, respectively.
Restricted Stock Unit and Restricted Stock Award Activity
RSU and RSA activity during the six months ended June 30, 2023, was as follows (in thousands, except per share amounts):
Restricted Stock Units and Restricted Stock Awards Outstanding
SharesWeighted Average Grant Date Fair Value
Outstanding as of December 31, 202254,518$25.46 
Granted 20,35824.50 
Released(14,308)24.68 
Forfeited(4,650)24.06 
Outstanding as of June 30, 202355,918$25.43 
Share-Based Compensation
Share-based compensation expense during the three and six months ended June 30, 2023 and 2022, was as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2023202220232022
Cost of revenue $2,740 $1,417 $5,049 $2,611 
Research and development108,580 81,436 202,845 134,326 
Sales and marketing26,398 18,501 45,587 30,270 
General and administrative 31,912 16,059 59,271 23,446 
Total share-based compensation $169,630 $117,413 $312,752 $190,653 
As of June 30, 2023, we had $1,380.6 million of unrecognized share-based compensation expense, which we expect to recognize over a weighted-average period of 2.6 years.
Stock Repurchase
On February 2, 2023, our board of directors authorized a stock repurchase program of up to $500.0 million of our Class A common stock, which we completed in the second quarter of 2023. Under the program, we repurchased and retired 21,215,663 shares of our Class A common stock for an aggregate purchase price of $500.5 million, including $0.5 million excise tax resulting from the Inflation Reduction Act of 2022.